{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-034006","form_type":"8-K","ticker":"FBLG","cik":"0001958777","company_name":"FibroBiologics, Inc.","filed_at":"2024-08-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.272603+00:00","generated_at":"2026-05-31T07:29:43.524723+00:00","sec_items":["3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"FibroBiologics reports $3.9M gross proceeds from GEM equity line draw downs","bullets":["On Aug 26, 2024, sold 100,000 shares at net $4.51 (10% discount), gross $451K.","Prior draw down: 840,000 shares at net $4.09, gross $3,436K; 560,000 shares returned for cancellation.","Aggregate gross proceeds from GEM SPA subsequent to June 30, 2024: $3,887K.","Remaining 1,500,000 shares from July 12 draw down returned to Company and cancelled."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-034006","json":"https://secwatch.observer/filing/0001493152-24-034006.json","markdown":"https://secwatch.observer/filing/0001493152-24-034006.md","text":"https://secwatch.observer/filing/0001493152-24-034006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224034006/0001493152-24-034006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1958777/000149315224034006/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T07:29:43.524723+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}